Company / Current Liabilities
Mineralys Therapeutics, Inc. Current Liabilities History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$14.6M
FY2024
5-year range
$8.1M / $14.6M
FY2022-FY2024
Trend
+39.7%
vs FY2023
Sector context
#198 of 213
Health Care
What the data says
Among 213 Health Care companies, Mineralys Therapeutics, Inc. is in the top 7% for current liabilities. Increased from $8M to $15M over the past 2 years.
Based on SEC 10-K filings.
$15M in FY2024.
Increased from $8M to $15M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 213This company $14.6M Sector average $1.6B
▼
-99.1% below sector average
Key checks
Key Insights
- In FY2024, current liabilities increased 39.7% year-over-year.
- Ranks #198 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $14.6M | +39.7% |
| FY2023 | $10.5M | +29.9% |
| FY2022 | $8.1M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026